DELFLEX PERIT.DIAL.SOL.4.25%DEX.LOW CALOW MG 448 MG / 100 ML
SODIUM LACTATE : 448 MG / 100 ML DEXTROSE : 4.25 G / 100 ML CALCIUM CHLORIDE : 18.4 MG / 100 ML SODIUM CHLORIDE : 538 MG / 100 ML MAGNESIUM CHLORIDE : 5.08 MG / 100 ML · DIN 02025930 · FRESENIUS USA MANUFACTURING INC
Health Canada status: CANCELLED POST MARKET
What is DELFLEX PERIT.DIAL.SOL.4.25%DEX.LOW CALOW MG?
DELFLEX PERIT.DIAL.SOL.4.25%DEX.LOW CALOW MG 448 MG / 100 ML contains SODIUM LACTATE : 448 MG / 100 ML DEXTROSE : 4.25 G / 100 ML CALCIUM CHLORIDE : 18.4 MG / 100 ML SODIUM CHLORIDE : 538 MG / 100 ML MAGNESIUM CHLORIDE : 5.08 MG / 100 ML. It is listed in the Health Canada Drug Product Database under DIN 02025930, held by FRESENIUS USA MANUFACTURING INC, supplied as SOLUTION for INTRAPERITONEAL administration. Health Canada currently lists it as cancelled post market, status dated 26-Jul-2016. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02025930 |
|---|---|
| Brand name | DELFLEX PERIT.DIAL.SOL.4.25%DEX.LOW CALOW MG |
| Generic / active ingredient | SODIUM LACTATE : 448 MG / 100 ML DEXTROSE : 4.25 G / 100 ML CALCIUM CHLORIDE : 18.4 MG / 100 ML SODIUM CHLORIDE : 538 MG / 100 ML MAGNESIUM CHLORIDE : 5.08 MG / 100 ML |
| Manufacturer | FRESENIUS USA MANUFACTURING INC |
| Strength | 448 MG / 100 ML |
| Dosage form | SOLUTION |
| Route of administration | INTRAPERITONEAL |
| Schedule | Ethical |
| ATC code | B05DB HYPERTONIC SOLUTIONS |
| AHFS class | 40:36.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 26-Jul-2016 |
| Original market date | 1994-12-31 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02025930 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2025930 |
| Brand name | DELFLEX PERIT.DIAL.SOL.4.25%DEX.LOW CALOW MG |
| Active ingredient / INN | SODIUM LACTATE : 448 MG / 100 ML DEXTROSE : 4.25 G / 100 ML CALCIUM CHLORIDE : 18.4 MG / 100 ML SODIUM CHLORIDE : 538 MG / 100 ML MAGNESIUM CHLORIDE : 5.08 MG / 100 ML |
| ATC code | B05DB |
| ATC anatomical main group | B — Blood and blood-forming organs |
| ATC therapeutic subgroup | B05 |
| AHFS class | 40:36.00 |
| Health Canada schedule | Ethical |
| Biosimilar biologic | No |
| Market authorization holder | FRESENIUS USA MANUFACTURING INC |
Which pack is which?
| Strength on the label | 448 MG / 100 ML |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAPERITONEAL |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
What can be used instead?
Other Canadian products sharing ATC code B05DB HYPERTONIC SOLUTIONS. 3 of 21 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| BALANCE 1.5% GLUCOSE, 1.25 MMOL/L CALCIUM | 0.1838 G | SOLUTION | FRESENIUS MEDICAL CARE CANADA INC | MARKETED | DIN 02261057 |
| BALANCE 2.3% GLUCOSE, 1.25 MMOL/L CALCIUM | 0.1838 G | SOLUTION | FRESENIUS MEDICAL CARE CANADA INC | MARKETED | DIN 02261073 |
| BALANCE 4.25% GLUCOSE, 1.25 MMOL/L CALCIUM | 0.1017 G | SOLUTION | FRESENIUS MEDICAL CARE CANADA INC | MARKETED | DIN 02261065 |
| BALANCE 1.5% GLUCOSE, 1.75 MMOL/L CALCIUM | 0.2573 G | SOLUTION | FRESENIUS MEDICAL CARE CANADA INC | APPROVED | DIN 02261022 |
| BALANCE 2.3% GLUCOSE, 1.75 MMOL/L CALCIUM | 0.2573 G | SOLUTION | FRESENIUS MEDICAL CARE CANADA INC | APPROVED | DIN 02261049 |
| BALANCE 4.25% GLUCOSE, 1.75 MMOL/L CALCIUM | 0.1017 G | SOLUTION | FRESENIUS MEDICAL CARE CANADA INC | APPROVED | DIN 02261030 |
| BICAVERA 1.5% GLUCOSE | 0.2573 G | SOLUTION | FRESENIUS MEDICAL CARE CANADA INC | CANCELLED PRE MARKET | DIN 02299682 |
| BICAVERA 2.3% GLUCOSE | 25.0 G | SOLUTION | FRESENIUS MEDICAL CARE CANADA INC | CANCELLED PRE MARKET | DIN 02299690 |
| BICAVERA 4.25% GLUCOSE | 5.786 G | SOLUTION | FRESENIUS MEDICAL CARE CANADA INC | CANCELLED PRE MARKET | DIN 02299704 |
| BICAVERA FORTE 1.5% GLUCOSE | 0.3675 G | SOLUTION | FRESENIUS MEDICAL CARE CANADA INC | CANCELLED PRE MARKET | DIN 02269384 |
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.